Efficacy of Low-Dose Adjunctive Methylphenidate Extended-Release on Cognition and Functioning in Individuals With Schizophrenia: A Randomized Open-Label Trial

PURPOSE/BACKGROUND: Cognitive impairment severely disrupts functioning and recovery in schizophrenia. Methylphenidate extended-release (ER) shows promise for cognition in attention-deficit/hyperactivity disorder but has limited, inconsistent evidence in schizophrenia. This study investigates low-dose methylphenidate ER’s effects on cognitive and functional outcomes in schizophrenia, addressing a critical therapeutic gap.

via https://pubmed.ncbi.nlm.nih.gov/41582768/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1HYeX0emtvYgH07Wkz0a8n9otrdMd-JIklc_uo0I5vh1u9WMEy&fc=None&ff=20260127010807&v=2.18.0.post22+67771e2